Annalee Armstrong on Muck Rack

Annalee Armstrong

Verified
Ottawa
As seen in: BioSpace, LinkedIn, S&P Global Market Intelligence, S&P Global, S&P Global Commodity Insights, Genetic Literacy Project, NewsBreak, Fierce Pharma, Fierce Biotech, fiercebiotechresearch.com, Clinical Leader and
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Annalee

Contact Annalee, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Incyte’s stars align as new CEO strikes $2B Vega takeover for blood disorder asset

|
By Annalee Armstrong 
| BioSpace
Incyte is adding a star to its constellation of hematology assets with the acquisition of Vega Therapeutics for up to $2 billion. Vega, a subsidiary of Star Therapeutics, will bring VGA039, a monocolonal antibody in Phase 3 development for the bleeding disorder von Willebrand disease (VWD). Incyte is paying Star $1.25 billion up front, plus $750 million in potential milestones. The deal is expected to close in the third quarter.
Open in Who Shared Issue with article?

ADA: Kailera ‘back at work’ after record-breaking IPO with China data in hand

|
By Annalee Armstrong 
| BioSpace
Kailera Therapeutics’ bridging study revealed over the weekend at the American Diabates Association Scientific Sessions provided evidence that the biotech’s lead obesity asset worked in a non-Asian population. It’s a check the box moment, Chief Commercial Officer Jamie Coleman told BioSpace—one that could be seen as a run-of-the-mill update. But Kailera isn’t a run-of-the-mill company.
Open in Who Shared Issue with article?

ADA: Lilly’s weight loss mastery shows benefits in menopause, sleep apnea, more

|
By Annalee Armstrong 
| BioSpace
Lilly’s tour de force landed in New Orleans over the weekend with weight loss studies showing the prowess of newly approved oral Foundayo and up-and-coming triple agonist retatrutide. First on the docket was a presentation spanning multiple studies of retatrutide and showing benefits across weight loss, A1C, knee pain and sleep apnea. Lilly had already revealed that patients who took retatrutide in the Phase 3 TRIUMPH-1 trial achieved 28.3% weight loss, or 70 pounds, at 80 weeks.
Open in Who Shared Issue with article?
See all 1,551 licensed articles (1,675 Total)

Actions

Share this page

Get in touch with Annalee

Contact Annalee, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified